PT-141: The Peptide That Targets Desire, Not Blood Flow — and Why Its FDA Approval Barely Made a Dent

The short version

PT-141 (bremelanotide / Vyleesi) is the only FDA-approved peptide that targets sexual desire. It was approved in June 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women.
It works through an entirely different mechanism than Viagra or Cialis. PDE5 inhibitors increase blood flow. PT-141 activates melanocortin receptors (MC3/MC4) in the brain’s hypothalamus, targeting desire itself — not the physical mechanics.
In Phase 3 trials (1,247 women), PT-141 significantly improved desire scores and reduced distress. But the effect size was modest: 25% responder rate vs 17% placebo.
The 40% nausea rate is the biggest practical barrier. Flushing (20%), headache (11%), and injection site reactions (13%) add up. 18% of trial participants discontinued due to side effects.
PT-141 was derived from Melanotan II — a tanning peptide developed at the University of Arizona in the 1980s. The sexual effects were discovered accidentally.
Vyleesi has been a commercial failure: $4.9M first-year revenue, manufacturer AMAG collapsed, rights changed hands twice. At ~$290/dose, most people access PT-141 through compounding pharmacies instead.
Men use PT-141 off-label with emerging evidence: a 2024 observational study showed 80% of men were more satisfied, and 34% of Viagra non-responders responded to PT-141.
Melanotan II (the non-selective predecessor) remains widely used underground for tanning despite being illegal for human use. Testing shows products contain as low as 43% of claimed content with up to 6% unknown impurities.

A tanning drug that accidentally discovered desire

In the 1980s, two scientists at the University of Arizona — Victor Hruby (a peptide chemist) and Mac Hadley (an endocrinologist) — were trying to develop a drug that could tan skin without sun exposure. The idea was to stimulate melanocytes (the cells that produce melanin) by activating melanocortin receptors.

They synthesized a compound called Melanotan II — a cyclic peptide that hit multiple melanocortin receptors, including MC1 (skin pigmentation), MC3 and MC4 (expressed in the brain’s hypothalamus).

During early testing, something unexpected happened. A researcher accidentally administered a double dose of Melanotan II to himself. Within hours, he developed severe nausea — and an eight-hour erection.

That accident redirected an entire research program.

The first formal human study confirmed it: Dorr et al. (1996) gave Melanotan II to 10 male volunteers and documented spontaneous penile erections in 8 of them [PMID: 8637402]. Wessells et al. (2000) followed up with 10 men with erectile dysfunction and showed that 8 developed adequate erections — most without any visual or physical sexual stimulation [PMID: 11035391].

The tanning drug worked on desire. Not just arousal — desire. This was fundamentally different from Viagra (which had just launched in 1998), because Viagra works on blood flow. It helps mechanics, not motivation. Melanotan II was doing something in the brain that Viagra couldn’t touch.

The problem was selectivity. Melanotan II hit all five melanocortin receptor subtypes. It tanned your skin (MC1), it triggered desire (MC3/MC4), and it caused intense nausea. You couldn’t isolate the sexual effect from the side effects.

So Palatin Technologies took the Melanotan II structure and engineered a more selective version — a cyclic heptapeptide that targeted MC3 and MC4 while largely sparing MC1. Less tanning, same brain-level desire activation. They called it PT-141, later branded as bremelanotide.

How PT-141 works — desire vs mechanics

This is the most important thing to understand about PT-141, and what makes it genuinely novel.

Viagra and Cialis (PDE5 inhibitors) work peripherally. They increase blood flow to erectile tissue. They help you physically respond if you’re already aroused. They do nothing for desire. If you don’t want sex, Viagra won’t change that — it just makes the plumbing work better if you do.

PT-141 works centrally — in the brain. It binds to MC3 and MC4 receptors in the paraventricular nucleus of the hypothalamus, triggering a cascade (cAMP/PKA) that facilitates dopaminergic signaling in desire pathways. It targets the “wanting” — the motivation, the interest, the drive.

This is why PT-141 matters for people who:

Have desire that’s gone flat but whose physical function is fine
Don’t respond to PDE5 inhibitors (about 30% of ED patients)
Want to address the psychological/motivational dimension of sexual dysfunction, not just the vascular dimension

It’s also why the clinical data looks different. Viagra trials measure erection hardness and penetration success. PT-141 trials measure desire, distress, and satisfying sexual events. They’re measuring different things because they’re addressing different problems.

The FDA approval — and why it barely mattered

On June 21, 2019, the FDA approved bremelanotide (Vyleesi) for hypoactive sexual desire disorder (HSDD) in premenopausal women. It became the second FDA-approved treatment for HSDD, after flibanserin (Addyi, a daily oral pill approved in 2015).

The RECONNECT trials

The pivotal data came from the RECONNECT Phase 3 program — two randomized, double-blind, placebo-controlled trials enrolling 1,247 premenopausal women with HSDD.

Design: Patients self-administered 1.75 mg subcutaneous injection at least 45 minutes before anticipated sexual activity. Maximum: once per day, 8 doses per month.

Results:

Desire scores (FSFI-D) improved significantly vs placebo (p<0.001)
Distress scores (FSDS-DAO) improved significantly vs placebo (p<0.001)
Responder rate: ~25% showed clinically meaningful improvement vs ~17% placebo
Satisfying sexual events: No statistically significant increase over placebo
52-week open-label extension (684 women) showed maintained efficacy and safety

The nuance nobody discusses: PT-141 significantly improved desire and significantly reduced distress about low desire — but did not significantly increase the number of satisfying sexual events. This means women wanted sex more and felt less bothered by their low desire, but the increase in wanting didn’t consistently translate to more sex they’d describe as satisfying. That’s a more complex outcome than the marketing suggests.

Side effects — the real barrier

Side effect	PT-141	Placebo
Nausea	40.0%	1.3%
Flushing	20.3%	0.3%
Headache	11.3%	1.9%
Injection site reactions	5.4-13.2%	—
Injection site bruising	6.2%	0.6%
Nasopharyngitis	3.5%	1.3%

Nausea specifics: Median onset 30 minutes after injection. Median duration 2.4 hours. Severe in 2.1%. Caused treatment discontinuation in 8.1% of all participants.

Total discontinuation due to any adverse event: 18% (vs 2% placebo).

Almost 1 in 5 women who tried Vyleesi stopped because of side effects. Mostly nausea.

The prescribing details

Dose: 1.75 mg subcutaneous, self-administered via auto-injector
Timing: At least 45 minutes before anticipated sexual activity
Maximum: Once per day, no more than 8 doses per month
Contraindicated: Uncontrolled hypertension, cardiovascular disease
No black box warning. No REMS (Risk Evaluation and Mitigation Strategy).

Why it was only approved for premenopausal women

The RECONNECT trials enrolled only premenopausal women. The FDA approved what was studied. Postmenopausal HSDD was not included in the trial population, so it wasn’t included in the label. The underlying biology (melanocortin receptors) is the same regardless of menopausal status, but the regulatory requirement is clear: prove it in each population separately.

For men, bremelanotide has shown efficacy in Phase 2 trials for erectile dysfunction, and Palatin Technologies initiated a Phase 2 combination trial (PT-141 + PDE5 inhibitor) in 2024. But the FDA approval path for men remains years away.

The commercial disaster

Vyleesi launched in September 2019 at approximately $290 per dose (per single-use auto-injector).

Year 1 revenue: $4.9 million. For a drug that cost hundreds of millions to develop and bring to market.

What went wrong:

Price. $290 per sexual encounter. Insurance coverage was inconsistent.
Nausea. 40% is a dealbreaker for a drug you take before sex.
The injection barrier. Self-injecting before sex is not a romantic prelude.
Modest efficacy. 25% responder rate vs 17% placebo — real but underwhelming.
The “female Viagra” framing backfired. By comparing it to Viagra, expectations were set for a simple, reliable, dramatic effect. Women’s desire is multifactorial. A drug that works in 1 in 4 women, causes nausea in 4 in 10, and requires an injection doesn’t match the Viagra narrative.
AMAG Pharmaceuticals (the initial US marketer) had financial difficulties unrelated to Vyleesi and eventually returned rights to Palatin.
COVID-19 hit six months after launch, disrupting sexual health prescribing.

Palatin eventually sold US rights to Cosette Pharmaceuticals for $12M upfront. Under Cosette, sales have grown for 8 consecutive quarters — but from a tiny base. Vyleesi is alive but far from thriving.

The irony: a compound that genuinely works through a novel mechanism, with FDA approval and Phase 3 data, struggles commercially — while unapproved peptides with thin evidence bases sell millions through compounding pharmacies and gray markets.

PT-141 for men — the off-label picture

While Vyleesi is approved only for women, PT-141 is increasingly used off-label for men — primarily through compounding pharmacies and peptide clinics.

The clinical evidence in men

Phase 2 trials: Safarinejad (2008) studied 342 men with erectile dysfunction in a dose-finding trial, establishing that subcutaneous bremelanotide improved erectile function [PMID: related to Palatin development program].

Goldstein & Goldstein (2024): An observational study of 21 men using PT-141:

80% reported being more satisfied with their sexual experience
86% felt more at ease initiating sex
34% of PDE5 inhibitor non-responders responded to PT-141

That last number is significant. About 30% of men with ED don’t respond to Viagra or Cialis. PT-141 works through a completely different pathway, so non-response to one doesn’t predict non-response to the other.

Palatin’s next step: In 2024, Palatin initiated a Phase 2 trial combining bremelanotide with a PDE5 inhibitor — targeting both desire (central) and function (peripheral) simultaneously.

How men use it in practice

Community protocols (not clinically validated):

Dose: 0.5-2.0 mg subcutaneous (many start at 1.0 mg, below the 1.75 mg female dose)
Timing: 45-90 minutes before sexual activity
Frequency: As needed, typically 1-3 times per week
Nausea management: Start low (0.5 mg), take ondansetron (Zofran) 30 minutes before if needed

User reports consistently describe the effect as qualitatively different from PDE5 inhibitors — less of a mechanical response and more of a return of genuine desire and anticipation. Some report only desire effects, some only erectile effects, most report both.

Melanotan II — the unregulated predecessor

While PT-141 went through FDA approval, its parent compound Melanotan II never did. It remains widely used underground — not for sexual effects, but for tanning.

The underground tanning market

Melanotan II is sold illegally in most jurisdictions as a “tan jab” or “Barbie drug.” The appeal: injectable melanin stimulation that produces a deep tan without UV exposure (or with minimal UV to “activate” the melanin).

It’s prevalent in:

Gym and bodybuilding culture
Cosmetic/beauty communities (especially UK, Australia, Scandinavia)
Instagram and TikTok (despite platform bans on related hashtags)

The safety concerns are real

Product quality: Testing of underground Melanotan II products has found:

As low as 43% of claimed peptide content
Up to 6% unknown impurities
Documented bacterial contamination

Health authority warnings: The FDA, UK MHRA (banned 2019), Australian TGA, and multiple European agencies have issued warnings against Melanotan II use.

Melanoma concern: Five case reports document melanoma in Melanotan II users, all involving darkened pre-existing moles. However, three separate reviews (2013, 2021, and Böhm et al. 2025 [PMID: 39082868]) concluded that the melanoma risk cannot be conclusively established because users typically also have increased UV exposure — a known melanoma cause. The concern is plausible (stimulating melanocytes could theoretically promote melanocytic tumors) but not proven.

Other documented adverse events: Rhabdomyolysis (muscle breakdown), renal infarction, severe nausea, facial flushing, darkening of moles and freckles (reversible on cessation).

Why Melanotan II was never approved

It’s a non-selective melanocortin agonist — it hits MC1 (skin), MC3/MC4 (sexual), and MC5 (sebaceous glands) without discrimination. The side effect profile made it unapprovable as a tanning drug: you can’t market a cosmetic product that causes nausea and erections. PT-141 exists specifically because the selectivity problem needed solving.

The melanocortin receptor system — why all this is connected

Receptor	Location	Function	PT-141	Melanotan II
MC1	Skin melanocytes	Pigmentation	Minimal	Strong
MC2	Adrenal cortex	Cortisol release (ACTH)	None	None
MC3	Hypothalamus	Sexual function, energy	Yes	Yes
MC4	Hypothalamus	Sexual function, appetite, energy	Yes	Yes
MC5	Sebaceous glands	Sebum production	Minimal	Yes

PT-141’s selectivity for MC3/MC4 over MC1 is why it produces desire effects with less tanning than Melanotan II. But “less” is not “none” — the Vyleesi label notes potential skin darkening as a side effect, particularly in darker-skinned individuals, though it was uncommon in trials.

PT-141 vs other sexual health options

	PT-141	Viagra/Cialis	Flibanserin (Addyi)	Kisspeptin	Testosterone
Target	Brain (desire)	Blood flow (mechanics)	Brain (serotonin/dopamine)	Hormonal (GnRH)	Hormonal
Route	SC injection	Oral	Oral daily	IV (research only)	Various
Onset	45-60 min	30-60 min	Weeks	Minutes	Weeks
FDA approved	Yes (women HSDD)	Yes (men ED)	Yes (women HSDD)	No	Yes (hypogonadism)
Nausea rate	40%	<3%	11%	Minimal	Minimal
Works for non-responders to PDE5i	Yes (34%)	N/A	Unknown	Unknown	Sometimes
Desire vs function	Desire	Function	Desire	Desire	Both

What this means for you

If you’re a woman with HSDD: PT-141/Vyleesi is one of only two FDA-approved options (alongside flibanserin). The 40% nausea rate is real — but 25% of women in trials had meaningful improvement. Starting at a lower dose (1.0 mg instead of 1.75 mg) and using anti-nausea medication may improve tolerability. Ask your gynecologist.

If you’re a man who doesn’t respond to Viagra/Cialis: PT-141 targets a completely different pathway. The early male data (34% response rate in PDE5i non-responders) is promising. Access is primarily through compounding pharmacies and peptide clinics. This is a legitimate medical conversation to have with a sexual health specialist.

If you’re considering Melanotan II for tanning: You’re using an unregulated, uncontrolled compound that testing shows contains highly variable content with unknown impurities. The melanoma risk is unproven but plausible. The nausea and other side effects are well-documented. Health authorities in multiple countries have explicitly warned against it.

If you’re interested in PT-141 but concerned about nausea: Start at 0.5 mg. Take ondansetron (Zofran) 30 minutes before if available. Nausea typically decreases with repeated use. The 2-4 hour nausea window is predictable — plan around it.

The bigger picture: PT-141 represents a genuine pharmacological advance — the first drug to target sexual desire through brain melanocortin pathways rather than peripheral blood flow. The science is real. The FDA approval is real. The commercial failure reflects pricing, delivery method, and side effect challenges — not a lack of efficacy. As compounded PT-141 becomes more accessible and combination therapies advance, this compound’s best days may still be ahead.

Sources

Dorr R.T. et al. “Effects of Melanotan-II on the human.” Life Sci. 1996;58(16):1353-62. PMID: 8637402
Wessells H. et al. “Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction.” Urology. 2000;56(4):641-6. PMID: 11035391
FDA Vyleesi approval, June 21, 2019. NDA 210557.
RECONNECT Phase 3 trials — two RCTs, n=1,247 premenopausal women with HSDD.
52-week RECONNECT open-label extension, n=684.
Vyleesi prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
Goldstein I. & Goldstein S.W. (2024) Observational study of PT-141 in men (n=21). 80% satisfaction, 34% PDE5i non-responder response.
Safarinejad M.R. (2008) Phase 2 bremelanotide in 342 men with ED.
Clayton A.H. et al. (2016) Phase 2B dose-finding study, n=394 premenopausal women.
Palatin Technologies Phase 2 bremelanotide + PDE5i combination trial, initiated 2024.
Diamond L.E. et al. (2004) Intranasal bremelanotide Phase 1. PMID: 15170063
Rosen R.C. et al. (2004) Subcutaneous bremelanotide in ED. [PMID: related Palatin data]
FDA 2007 clinical hold on intranasal bremelanotide — blood pressure concerns.
AMAG Pharmaceuticals — Vyleesi first-year revenue $4.9M.
Cosette Pharmaceuticals acquisition of Vyleesi US rights, $12M upfront (from Palatin total deal $171M).
Böhm M. et al. (2025) Melanotan II melanoma risk review. PMID: 39082868
2013 systematic review — Melanotan II and melanoma risk.
2021 analysis — Melanotan II melanoma attribution to UV co-exposure.
Melanotan II product quality testing — 43% of claimed content, up to 6% unknown impurities.
UK MHRA Melanotan II ban, 2019.
FDA consumer warning on Melanotan II.
Australian TGA Melanotan II warning.
King Pharmaceuticals partnership with Palatin, $20M.
AMAG Pharmaceuticals $60M deal with Palatin.
Vyleesi commercial performance: $12.5M gross FY2023 under Cosette; 8 consecutive quarters double-digit growth.
WADA Prohibited List — bremelanotide and Melanotan II.